Full-Time
Senior Software QA Engineer 1
Posted on 11/21/2024
iRhythm Technologies
1,001-5,000 employees
Advanced cardiac monitoring solutions provider
Compensation Overview
$112k - $145kAnnually
Mid, Senior
San Francisco, CA, USA
Local telecommuting permitted up to 4 days per week.
- Bachelor’s degree in Computer Science, Business Administration or a related field of study
- three (3) years of Software QA experience
- Functional manual test creation
- Web services and APIs testing (Postman)
- Analytical and problem-solving skills, finding creative solutions
- Working in an Agile development environment
- Collaborating with other engineers
- Presenting methods and observations
- Programming experience in one or more of the following languages: Java, Python, C/C++, and/or .NET/C#
- Experience in HIPAA testing privacy with multiple transaction exposure and knowledge in Medicare and Medicaid
- Working knowledge of AWS or other Cloud Platforms
- Developing automated tests
- Proficiency with MySQL in Linux environment
- Understanding of Test-Driven Development and related use of unit testing approaches and tools (e.g., JUnit)
- plan, design, and execute system-level testing of the cardiac monitoring devices and supporting software applications
- Develop written verification protocols and subsequently document and report test results to both functional and customer requirements, in a manner consistent with regulatory and internal standards
- Review software requirements and design documentations to ensure technical accuracy as well as testability
- Act as a quality advocate throughout the development cycle with a focus on end-user (internal, external, patient) needs
- Provide estimates for Software QA efforts required based on protocols developed
- Seek out opportunities to automate labor intensive manual tests and work with automation engineers on roadmaps and prioritization
- Plan, design, and execute testing using Agile methodology
iRhythm Technologies specializes in cardiac monitoring solutions, primarily through its product, the Zio Patch. This wearable device allows for up to 14 days of continuous heart rhythm tracking, enabling healthcare providers to detect irregular heart rhythms that may not be identified during shorter monitoring periods. The Zio Patch is particularly useful for patients who suspect heart rhythm issues, as it allows them to monitor their heart activity without frequent visits to healthcare facilities, which is especially important in the context of telehealth and COVID-19. Unlike many competitors, iRhythm not only provides the monitoring device but also offers data analysis services that interpret the collected data, giving healthcare providers actionable insights. The company's goal is to enhance patient outcomes and improve healthcare workflows by making cardiac monitoring more accessible and efficient.
Company Stage
IPO
Total Funding
$102.8M
Headquarters
San Francisco, California
Founded
2006
6 month growth
↑ 1%1 year growth
↑ 7%2 year growth
↑ 23%
Simplify's Take
What believers are saying
- Growing interest in wearable health tech boosts demand for Zio Patch.
- FDA approval of Zio AT supports market expansion and compliance.
- European expansion of Zio services captures international market share.
What critics are saying
- Increased competition may impact iRhythm's market share.
- FDA warning letter could lead to regulatory scrutiny and fines.
- Shareholder investigation may result in legal challenges and liabilities.
What makes iRhythm Technologies unique
- Zio Patch offers up to 14 days of uninterrupted cardiac monitoring.
- iRhythm's exclusive license with BioIntelliSense enhances its ambulatory cardiac monitoring capabilities.
- Zio Patch is the smallest and least conspicuous cardiac arrhythmia diagnostic device available.
Help us improve and share your feedback! Did you find this helpful?